hylan G-F 20, Synvisc
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: hylan G-F 20
BRAND NAME: Synvisc, Synvisc-One
DRUG CLASS AND MECHANISM: Hylan G-F 20 is an injectable fluid that is used to treat osteoarthritis of the knee. Osteoarthritis is a type of arthritis in which the joints of the body degenerate and become painful and stiff. Osteoarthritis is the most common form of arthritis; almost 10 million Americans suffer from osteoarthritis. Most affected persons are over 45 years of age, and women are more often affected than men. Joints contain a fluid, called synovial fluid, which acts as a lubricant and shock absorber. Patients with osteoarthritis have synovial fluid that is thinner than normal, and, therefore, it is less effective as a lubricant and shock-absorber. Hylan G-F 20 is an elastic fluid that is made from a substance called hyaluronan, that is found in normal joint fluid. Hyaluronan is the key substance in joint fluid that provides the shock-absorbing quality to the fluid, and it is essential for the proper functioning of joints. When injected into the knee of a patient with osteoarthritis, hylan G-F 20 helps to restore the shock-absorbing effect of the fluid within the knee. This can reduce pain, resulting in a more active lifestyle.
PREPARATIONS: Injection: 16 mg/2 ml, 48 mg/6 ml
STORAGE: hyland G-F 20 should be stored at room temperature, below 86 F (30 C). Any unused solution should be thrown out. It should not be frozen.
PRESCRIBED FOR: Hylan G-F 20 is used for treating pain caused by osteoarthritis of the knee.
DOSING: Hylan G-F 20 is injected into the knee by a health professional. A course of treatment consists of three injections with each injection seven days apart when using Synvisc. Alternatively Synvisc-One, which contains all 3 doses (48 mg/ 6 ml) can be injected once as a single injection. Most people experience the greatest amount of relief from pain 8 to 12 weeks after beginning treatment. Some patients will require more than one course of treatment.
DRUG INTERACTIONS: There are no known drug interactions with hylan G-F 20.
PREGNANCY: No adequate studies have been done in pregnant women.
NURSING MOTHERS: The risks of hylan G-F 20 during breastfeeding are not known. It is not known if hylan G-F 20 is excreted into breast milk.
SIDE EFFECTS: About 1 in 14 persons experience pain or swelling in the injected knee, and one third of those who do, need to have fluid removed from the knee. Injection site pain, stiffness, and redness also occur. About 1 in 50 may experience a skin rash or itching. Facial flushing and swelling have been reported.
Reference: FDA Prescribing Information
Last Editorial Review: 8/1/2012
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index